对于精神分裂症的性疗法:证据,机制和临床前景
Cristiano Chaves1,2, Jennifer Fabe3, Fabiano A Gomes2
1NeuroMood Lab, Department of Psychiatry, School of Medicine and Kingston Health Sciences Centre (KHSC), Queen's University, Kingston, ON, Canada.
Frontiers in pharmacology
|July 10, 2025
概括
低碳水化合物饮食的热疗法显示出作为精神分裂症辅助治疗的前景. 它可以通过向代谢途径和增强大脑能量代谢来改善症状和认知功能.
科学领域:
- 神经科学是一个神经科学.
- 代谢精神病学 代谢精神病学
- 营养精神病学 营养精神病学
背景情况:
- 精神分裂症涉及认知和功能障碍,目前的治疗方法不足以解决负面症状和认知缺陷.
- 抗精神病药物可以使代谢问题恶化,突出显示需要替代干预措施.
- 葡萄糖代谢受损和线粒体功能障碍在精神分裂症的病理生理学中越来越被认可.
研究的目的:
- 审查和综合关于基因疗法作为精神分裂症潜在辅助治疗的证据.
- 探索在精神分裂症谱系障碍中使用基干预措施的临床,临床前和机制基础.
主要方法:
- 对临床发现的审查,包括病例报告和小型试验.
- 使用NMDA对抗剂模型进行的临床前研究分析.
- 关于体效应的机械证据的综合.
主要成果:
- 初步数据表明,基因疗法可以改善精神分裂症的积极/消极症状,认知和代谢结果.
- 临床前研究表明,性干预可以使行为和神经生理缺陷正常化.
- 机制包括增强的线粒体功能,神经递质调节,减少炎症/氧化应激.
结论:
- 性疗法是一种新的方法,针对精神分裂症的代谢和神经化学途径.
- 它可以解决未满足的需求,如负面/认知症状,耐治疗性和代谢综合征.
- 需要进行更大规模的试验来确认精神病治疗的有效性,安全性和可行性.
相关概念视频
Psychosis: Goals of Pharmacotherapy
213
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
213
Drug Therapy
107
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
107
Psychosis and Antipsychotic Drugs: Overview
465
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
465
Electroconvulsive Therapy
200
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
200
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
999
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
999
Diabetes: Management and Pharmacotherapy
408
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
408


